Salmon Calcitonin Use and Associated Cancer Risk

Annals of Pharmacotherapy

Volumn 47, Issue 12, 2013, Pages 1675-1684

  Overman, Robert A ^a   Borse, Mrudula ^a   Gourlay, Margaret L ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

calcitonin; cancer; drug safety; fracture; osteoporosis; pharmacovigilance; salmon calcitonin

Indexed keywords

PLACEBO; SALCATONIN;

BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER RISK; DRUG APPROVAL; DRUG SAFETY; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION PROCESSING; KNEE OSTEOARTHRITIS; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW;

CALCITONIN; CANCER; DRUG SAFETY; FRACTURE; OSTEOPOROSIS; PHARMACOVIGILANCE; SALMON CALCITONIN;

CALCITONIN; HUMANS; NEOPLASMS; OSTEOPOROSIS; RISK;

EID: 84891640228     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013509233     Document Type: Review

References (59)

1. Copp DH,Cameron EC,Cheney BA,Davidson AG,Henze KG.Evidence for calcitonin: a new hormone from the parathyroid that lowers blood calcium.Endocrinology. 1962;70:638-649.
2. Copp DH.Calcitonin: discovery, development, and clinical application.Clin Invest Med. 1994;17:268-277.
3. Azria M,Copp DH,Zanelli JM.25 Years of salmon calcitonin: from synthesis to therapeutic use.Calcif Tissue Int. 1995;57:405-408.
4. US Food and Drug Administration. Drugs@FDA: FDA approved drug products, label and approval history, Miacalcin (nasal). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=020313&DrugName=MIACALCIN&ActiveIngred=CALCITONIN%20SALMON&SponsorApplicant=NOVARTIS&ProductMktStatus=1&goto=Search.DrugDetails. Accessed September 21, 2013.
5. US Food and Drug Administration. Drugs@FDA: FDA approved drug products, label and approval history, Miacalcin (injectable). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=017808&DrugName=MIACALCIN&ActiveIngred=CALCITONIN%20SALMON&SponsorApplicant=NOVARTIS&ProductMktStatus=3&goto=Search.DrugDetails. Accessed September 21, 2013.
6. Henriksen K,Bay-Jensen AC,Christiansen C,Karsdal MA.Oral salmon calcitonin: pharmacology in osteoporosis.Expert Opin Biol Ther. 2010;10:1617-1629.
7. Chesnut CH,Azria M,Silverman S,Engelhardt M,Olson M,Mindeholm L.Salmon calcitonin: a review of current and future therapeutic indications.Osteoporos Int. 2008;19:479-491.
8. Chesnut CH,Silverman S,Andriano Ket al.A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study. PROOF study group.Am J Med. 2000;109:267-276.
9. Overgaard K,Riis BJ,Christiansen C,Hansen MA.Effect of salcatonin given intranasally on early postmenopausal bone loss.BMJ. 1989;299:477-479.
10. Overgaard K.Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.Calcif Tissue Int. 1994;55:82-86.
11. Ellerington MC,Hillard TC,Whitcroft SIet al.Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.Calcif Tissue Int. 1996;59:6-11.
12. Watts NB,Worley K,Solis A,Doyle J,Sheer R.Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.J Manag Care Pharm. 2004;10:142-151.
13. Hochberg M.Preventing fractures in postmenopausal women with osteoporosis: a review of recent controlled trials of antiresorptive agents.Drugs Aging. 2000;17:317-330.
14. CrandallCJNewberrySJDiamantA. Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report: Comparative Effectiveness Review No. 53. http://www.effectivehealthcare.ahrq.gov/ehc/products/160/1007/CER53_LowBoneDensity_FinalReport_20120823.pdf. Accessed September 21, 2013.
15. US Food and Drug Administration. Drugs@FDA: FDA approved drug products, label and approval history, Fortical. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=021406&DrugName=FORTICAL&ActiveIngred=CALCITONIN%20SALMON%20RECOMBINANT&SponsorApplicant=UPSHER%20SMITH&ProductMktStatus=1&goto=Search.Label_ApprovalHistory. Accessed September 21, 2013.
16. Miacalcin Team. Drug Regulatory Affairs, Miacalcin® (calcitonin-salmon), FDA Joint Reproductive Health Drugs and Drug Safety and Risk Management advisory committee meeting on the benefit/risk of salmon calcitonin for the treatment of postmenopausal osteoporosis (Novartis Briefing Book). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM341781.pdf. Accessed September 21, 2013.
17. United States Department of Health and Human Services, Food and Drug Administration. Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM341779.pdf. Accessed September 21, 2013.
18. Karsdal MA,Henriksen K,Bay-Jensen ACet al.Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.J Clin Pharmacol. 2011;51:460-471.
19. Bagger YZ,Tanko LB,Alexandersen Pet al.Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis.Bone. 2005;37:425-430.
20. Binkley N,Bolognese M,Sidorowicz-Bialynicka Aet al.A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.J Bone Miner Res. 2012;27:1821-1829.
21. Karsdal MA,Byrjalsen I,Henriksen Ket al.The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study.Osteoarthritis Cartilage. 2010;18:150-159.
22. Manicourt DH,Azria M,Mindeholm L,Thonar EJ,Devogelaer JP.Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis.Arthritis Rheum. 2006;54:3205-3211.
23. Nielsen RH,Bay-Jensen AC,Byrjalsen I,Karsdal MA.Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover.Osteoarthritis Cartilage. 2011;19:466-473.
24. Tanko LB,Bagger YZ,Alexandersen Pet al.Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.J Bone Miner Res. 2004;19:1531-1538.
25. US Department of Health and Human Services. Postmarketing surveillance programs. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ucm090385.htm. Accessed September 21, 2013.
26. Cummings SR,Chapurlat RD.What PROOF proves about calcitonin and clinical trials.Am J Med. 2000;109:330-331.
27. Andrews NA.Calcitonin therapy: is the story coming to an end?.IBMS BoneKEy. 2013;10:.
28. ClinicalTrials gov. Nordic Bioscience A/S, Novartis. Efficacy and safety of oral salmon calcitonin in patients with knee osteoarthritis. http://clinicaltrials.gov/ct2/show/NCT00486434. Accessed September 21, 2013.
29. ClinicalTrials gov. Nordic Bioscience A/S, Novartis. Efficacy and safety of oral salmon calcitonin in patients with knee osteoarthritis (OA 2 study). http://clinicaltrials.gov/ct2/show/NCT00704847. Accessed September 21, 2013.
30. ClinicalTrials gov. Nordic Bioscience A/S, Novartis. A study to evaluate oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. http://clinicaltrials.gov/ct2/show/NCT00525798. Accessed September 21, 2013.
31. US Food and Drug Administration, Center for Drug Evaluation and Research, Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee Hearing, March5, 2013. Calcitonin Salmon for the Treatment of Postmenopausal Osteoporosis. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/reproductivehealthdrugsadvisorycommittee/ucm343748.pdf.
32. Shah GV,Rayford W,Noble MJet al.Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3',5'-monophosphates and cytoplasmic Ca2+ transients.Endocrinology. 1994;134:596-602.
33. Ritchie CK,Thomas KG,Andrews LR,Tindall DJ,Fitzpatrick LA.Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis.Prostate. 1997;30:183-187.
34. Segawa N,Nakamura M,Nakamura Y,Mori I,Katsuoka Y,Kakudo K.Phosphorylation of mitogen-activated protein kinase is inhibited by calcitonin in DU145 prostate cancer cells.Cancer Res. 2001;61:6060-6063.
35. Sondergaard BC,Catala-Lehnen P,Huebner AKet al.Mice over-expressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus.Osteoarthritis Cartilage. 2012;20:136-143.
36. Krause D,Hernandez N,Vitagliano M,Gilligan J,Buben C.One year use of oral recombinant salmon calcitonin is not associated with increased risk of cancer.J Bone Miner Res. 2012;27 (S1): S503.
37. European Medicines Agency. Questions and answers on the review of calcitonin-containing medicines. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Calcitonin_31/WC500134838.pdf. Accessed September 22, 2013.
38. Heep M,Lesperance S,Gasser J,Chen C,Aftring R.Calcitonin use and risk of malignancy: a meta-analysis of 17 RCTs in patients with osteoporosis.J Bone Miner Res. 2012;27 (S1): S486.
39. Arnala I,Saastamoinen J,Alhava EM.Salmon calcitonin in the prevention of bone loss at perimenopause.Bone. 1996;18:629-632.
40. ClarkeT. FDA panel advises calcitonin salmon not be used for osteoporosis. Reuters. March5, 2013. http://www.reuters.com/article/2013/03/05/us-fda-calcitonin-idUSBRE92418H20130305. Accessed September 21, 2013.
41. Health Canada. Synthetic calcitonin (salmon) nasal spray (NS): market withdrawal of all products, effective October 1st, 2013-For Health Professionals. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/34783a-eng.php. Accessed September 21, 2013.
42. Grigoriou O,Papoulias I,Vitoratos Net al.Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study.Maturitas. 1997;28:147-151.
43. Thamsborg G,Storm TL,Sykulski R,Brinch E,Nielsen HK,Sorensen OH.Effect of different doses of nasal salmon calcitonin on bone mass.Calcif Tissue Int. 1991;48:302-307.
44. Reginster JY,Denis D,Deroisy Ret al.Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.J Bone Miner Res. 1994;9:69-73.
45. Chesnut CH,Majumdar S,Newitt DCet al.Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.J Bone Miner Res. 2005;20:1548-1561.
46. Sacks H,Chalmers TC,Smith H.Randomized versus historical controls for clinical trials.Am J Med. 1982;72:233-240.
47. Concato J,Shah N,Horwitz RI.Randomized, controlled trials, observational studies, and the hierarchy of research designs.N Engl J Med. 2000;342:1887-1892.
48. LeLorier J,Gregoire G,Benhaddad A,Lapierre J,Derderian F.Discrepancies between meta-analyses and subsequent large randomized, controlled trials.N Engl J Med. 1997;337:536-542.
49. Bailar JC.The promise and problems of meta-analysis.N Engl J Med. 1997;337:559-561.
50. Hill AB.The environment and disease: association or causation?.Proc R Soc Med. 1965;58:295-300.
51. United States Department of Health and Human Services, Food and Drug Administration. Structured approach to benefit-risk assessment in drug regulatory decision-making. http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM329758.pdf. Accessed September 21, 2013.
52. Agency for Health Care Research and Quality. US preventive services task force procedures manual. http://www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual.pdf. Accessed September 21, 2013. AHRQ Publication No. 08-05118-EF.
53. Cranney A,Guyatt G,Griffith Let al.Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.Endocr Rev. 2002;23:570-578.
54. Wells GA,Cranney A,Peterson Jet al.Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.Cochrane Database Syst Rev. 2008; (1): CD001155.
55. Wells G,Cranney A,Peterson Jet al.Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.Cochrane Database Syst Rev. 2008; (1): CD004523.
56. Cummings SR,San Martin J,McClung MRet al.Denosumab for prevention of fractures in postmenopausal women with osteoporosis.N Engl J Med. 2009;361:756-765.
57. Blau LA,Hoehns JD.Analgesic efficacy of calcitonin for vertebral fracture pain.Ann Pharmacother. 2003;37:564-570.
58. Overgaard K,Hansen MA,Jensen SB,Christiansen C.Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.BMJ. 1992;305 (6853): 556-561.
59. Flicker L,Hopper JL,Larkins RG,Lichtenstein M,Buirski G,Wark JD.Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.Osteoporos Int. 1997;7:29-35.